читать далее ... , Moranaa SS.'et al. Do ACE inhibitors or angiotensin II antagonists reduce total mortality and arrhythmic mortality? A critical review of controlled clinical trials. Con Opin Cardiol 2002:17:6-18. 12. Cleland JG, Cohen-Solal A, Aguilar JC, et al IMPROVEMENT of Heart Failure Programme Committees and Investigators. Improvement programme in evaluation and management; Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of Cardiology Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet. 2002:360:1631-1639. 13. Davies M, Hobbs F, Davis R,et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet. 2001:358:439-444 14. Remme WJ. Riegger G, Hildebrandt P, et al The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther. 2004:18:57-66. 15. Sliwa К, Norton GR, Копе N, Candy G, Kachope J, Woodiwiss AJ, ' Libhaber C, Sareli P, Essop R. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J Am Coil Cardiol. 2004:44:1825-1830 16. M. Komaida, P. Lapuerta, N. Hermanc et. a/. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey E.H.J. 2005,26,1659-1659. Источник: Арутюнов Г.П. Русский медицинский журнал. 2006. Т.14. №2. С.137-142